metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
ovarian cancer (OC) ovarian cancer (OC)
mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.96 [0.74; 1.25], 1 RCT, I2=0% inconclusive result	0.92 [0.79; 1.07], 1 RCT, I2=0% inconclusive result	-
mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	0.98 [0.68; 1.41], 1 RCT, I2=0% inconclusive result	0.80 [0.65; 0.99], 1 RCT, I2=0% unassessable degree of certainty	-
metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	0.79 [0.44; 1.42], 1 RCT, I2=0% inconclusive result	0.53 [0.34; 0.82], 1 RCT, I2=0% unassessable degree of certainty	-
versus pegylated liposomal doxorubicin
	avelumab alone vs. pegylated liposomal doxorubicin	1	1.14 [0.88; 1.47], 1 RCT, I2=0% inconclusive result	1.68 [1.20; 2.36], 1 RCT, I2=0% statistically significant harm	-
	avelumab plus pegylated liposomal doxorubicin vs. pegylated liposomal doxorubicin	1	0.89 [0.69; 1.15], 1 RCT, I2=0% inconclusive result	0.78 [0.54; 1.13], 1 RCT, I2=0% inconclusive result	-
metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)